[
  {
    "question": "Patient presented with focal numbness on skin lesion, investigation revealed nerve enlargement around the lesion, attached picture of reddish skin patch, what is the diagnosis?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Lepro",
    "subspecialty": "Neuromuscular",
    "explanation": "Leprosy (Hansen\u2019s disease) is a chronic infectious disease caused by Mycobacterium leprae. It typically presents with skin lesions (which may be hypopigmented or reddish) accompanied by focal areas of anesthesia and palpable (thickened) peripheral nerves. M. leprae has a predilection for infecting Schwann cells in the peripheral nervous system, leading to segmental demyelination and nerve damage. The inflammatory response to the bacteria contributes to nerve enlargement and subsequent sensory loss. The bacterial affinity for cooler areas of the body explains the predilection for skin lesions. The combination of a distinct skin patch (reddish or hypopigmented) with localized numbness and palpable nerve enlargement is considered pathognomonic for leprosy. Patients may also present with muscle weakness or paralysis in more advanced cases due to nerve involvement. Diagnosis is primarily clinical. Differential diagnoses include conditions like herpes zoster (which shows painful, vesicular eruptions without nerve thickening), erythema nodosum (painful nodules without focal numbness), diabetic peripheral neuropathy (usually symmetric and distal), and cutaneous lymphoma. Confirmatory tests include slit-skin smears, skin biopsy with Fite stain to identify acid-fast bacilli, and nerve conduction studies in selected cases. The current WHO-recommended multi-drug therapy (MDT) regimen includes a combination of rifampin, dapsone, and clofazimine. For tuberculoid cases, the treatment duration is shorter compared to lepromatous cases. In pregnancy and lactation, MDT is generally considered safe; however, physicians should consult current guidelines as certain drugs (e.g., rifampin) require monitoring and counseling regarding potential side effects. Correct Answer: Leprosy. Other options such as herpes zoster, erythema nodosum, diabetic peripheral neuropathy, or cutaneous lymphoma do not present with the triad of a skin lesion with focal sensory loss and nerve enlargement. Herpes zoster, for example, presents with a painful, vesicular, dermatomal pattern but lacks nerve thickening. 1. A skin lesion with localized anesthesia and palpable nerve thickening is almost pathognomonic for leprosy. 2. Early diagnosis and treatment are essential to prevent irreversible nerve damage. 3. MDT has dramatically reduced the disease burden and transmission rates worldwide. Recent advances include molecular diagnostic techniques that help in the early detection of M. leprae and studies supporting the effectiveness and safety of current MDT regimens. Ongoing research aims to improve early detection and prevent nerve damage through immunomodulatory strategies.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient was diagnosed with Metachromatic Leukodystrophy, what you will find on NCS?",
    "option_a": "demyelinating neuropathy",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Metachromatic Leukodystrophy (MLD) is an inherited lysosomal storage disorder characterized by the accumulation of sulfatides due to a deficiency in the enzyme arylsulfatase A, leading to demyelination both centrally and peripherally. The deficiency in arylsulfatase A leads to the buildup of sulfatides within the myelin sheath, disrupting the normal structure and function of both central and peripheral nervous system myelin. This accumulation results in progressive demyelination, which is reflected in both neurological deficits and abnormal nerve conduction studies. Patients with MLD often present with progressive motor and cognitive decline. The demyelination of peripheral nerves typically leads to neuropathic features detectable on nerve conduction studies, most commonly a demyelinating neuropathy pattern. The diagnosis involves a combination of clinical assessment, nerve conduction studies (which reveal slowing consistent with demyelination), MRI to assess white matter abnormalities, and confirmatory enzyme assays (measurement of arylsulfatase A levels) along with genetic testing. Differential diagnoses include other leukodystrophies and demyelinating neuropathies caused by inflammatory conditions. Management of MLD is largely supportive. In early stages, hematopoietic stem cell transplantation (HSCT) may slow disease progression in select patients. There are no curative treatments currently. Management includes symptom control, physical therapy, and supportive care. Pregnancy and lactation considerations include multidisciplinary counseling since treatment options like HSCT require careful monitoring and are not typically initiated during pregnancy. Option A (demyelinating neuropathy) is correct because nerve conduction studies in MLD most typically demonstrate a demyelinating pattern. Other options (if provided) would not align with the expected electrophysiological findings in this condition. 1. MLD is a progressive demyelinating disease with both central and peripheral nervous system involvement. 2. A demyelinating pattern on nerve conduction studies is common. 3. Early diagnosis is important for considering available treatment options like HSCT. Recent studies have been focusing on gene therapy as a promising treatment option for MLD. Additionally, advances in enzyme replacement therapies and early diagnostic markers are being researched to improve patient outcomes.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 55 year old patient complaining of generalized weakness, weight gain. Complaining of tingling in her hands and has slight bradycardia. On exam she had delayed relaxation with deep tendon reflexes (case of hypothyroidism), what test to order?",
    "option_a": "Thyroid test",
    "option_b": "Ach receptor",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical scenario describes a patient with symptoms highly suggestive of hypothyroidism: generalized weakness, weight gain, tingling in the hands, bradycardia, and delayed relaxation of deep tendon reflexes. Hypothyroidism is characterized by low levels of thyroid hormones (T3 and T4), leading to a decrease in metabolic activity. The deficiency in thyroid hormones leads to the accumulation of mucopolysaccharides in tissues (myxedema), and slowing of neuromuscular conduction, resulting in the classic delayed reflex relaxation. The patient's symptoms of weight gain, generalized weakness, and bradycardia are typical for hypothyroidism. Delayed tendon reflexes are a sensitive clinical sign. Sometimes, patients may also experience paresthesias or tingling, which can occasionally mimic neuromuscular disorders but are secondary to metabolic slowdown. The first-line diagnostic test is thyroid function testing, including serum TSH and free T4 levels. Differential diagnoses include myasthenia gravis (characterized by fatigable weakness and positive acetylcholine receptor antibodies), depression, and other metabolic disorders \u2013 but the constellation of signs in this patient strongly favors hypothyroidism. First-line treatment for hypothyroidism is levothyroxine replacement. The dose is titrated based on TSH levels. In pregnancy and lactation, levothyroxine is safe and often doses need to be increased to meet the higher metabolic demands of pregnancy. Monitoring and adjusting the dosage are imperative during these periods. Option A (Thyroid test) is correct because it directly addresses the suspected diagnosis. Option B (Ach receptor test) is used for diagnosing myasthenia gravis, which is not consistent with the patient\u2019s clinical findings of metabolic slowing and myxedema. 1. Delayed tendon reflex relaxation is a classic sign of hypothyroidism. 2. Thyroid function tests (TSH and free T4) are the cornerstone of diagnosis. 3. Levothyroxine is safe and effective in both non-pregnant and pregnant populations. Latest guidelines emphasize early detection and treatment of hypothyroidism to prevent long-term complications. Current research also focuses on individualized dosing strategies, especially in pregnant patients, to optimize maternal and fetal outcomes.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "young man played football for 1 day developed generalized weakness mainly in the proximal limbs, the next day, his urine changed color to dark brown and had muscle pain, most likely cause?",
    "option_a": "CPT II deficiency",
    "option_b": "Urea cycle disorder",
    "option_c": "Acid maltase",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Carnitine palmitoyltransferase II (CPT II) deficiency is a metabolic myopathy that impairs the transport of long-chain fatty acids into mitochondria for beta-oxidation. This results in an energy deficit in muscle cells, particularly during prolonged exercise or stress. In CPT II deficiency, a defect in the enzyme responsible for the final step of fatty acid transport leads to an inability to utilize long-chain fatty acids as an energy source. During prolonged exercise, when energy demands are high, this defect results in muscle cell breakdown (rhabdomyolysis), manifesting as muscle pain and myoglobinuria (dark-colored urine). Patients with CPT II deficiency typically present with episodes of muscle pain, weakness (especially in the proximal muscles), and dark urine following strenuous exercise. The symptoms in this young man after playing football are classic for an exercise-induced episode of rhabdomyolysis due to CPT II deficiency. Evaluation includes measuring serum creatine kinase (CK) during attacks, urine analysis for myoglobin, acylcarnitine profiling, and genetic testing for mutations in the CPT2 gene. Differential diagnoses include other causes of exercise-induced rhabdomyolysis such as glycogen storage diseases (e.g., McArdle's disease) and inflammatory myopathies; however, the pattern of recurrent episodes triggered by prolonged exercise favors a metabolic defect like CPT II deficiency. Management primarily involves avoidance of known triggers such as prolonged exercise, fasting, and cold exposure. A high-carbohydrate, low-fat diet, and sometimes supplementation with medium-chain triglycerides may be recommended to bypass the metabolic block. During pregnancy and lactation, dietary management remains the mainstay, and careful monitoring is required; however, there are no specific contraindicated therapies. Patients should be counseled on lifestyle modifications to prevent episodes. Option A (CPT II deficiency) is correct. Urea cycle disorders (Option B) generally present with hyperammonemia and encephalopathy, not isolated muscle symptoms. Acid maltase deficiency (Option C, Pompe disease) typically presents with progressive muscle weakness and cardiomyopathy, and is not characteristically associated with exercise-induced rhabdomyolysis. 1. CPT II deficiency often presents with recurrent episodes of exercise-induced muscle pain and myoglobinuria. 2. A detailed history of exercise triggers is key to diagnosis. 3. Dietary modification can be effective in managing and preventing episodes. Recent studies have focused on confirming the diagnosis with acylcarnitine profiling and the potential benefits of medium-chain triglyceride supplementation. Ongoing research is evaluating targeted therapies and improved dietary strategies to reduce the frequency and severity of rhabdomyolysis episodes in affected individuals.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "filipino guy who did intense exercise, then developed generalized weakness with intact level of consciousness what is most useful to send for?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "K lev",
    "subspecialty": "Neuromuscular",
    "explanation": "This question focuses on the evaluation of a patient with exercise\u2010induced generalized weakness while maintaining an intact level of consciousness. The core idea is to suspect an electrolyte imbalance\u2014specifically hypokalemia\u2014which is a key feature of hypokalemic periodic paralysis. Hypokalemic periodic paralysis is commonly due to genetic ion channel mutations (e.g., in the CACNA1S or SCN4A genes) that lead to abnormal muscle membrane excitability. Intense exercise can trigger an intracellular shift of potassium, thereby lowering serum potassium levels and impairing muscle contraction. The condition may present as a primary channelopathy or secondarily (e.g., in thyrotoxic periodic paralysis). Patients typically experience an acute onset of weakness after triggers such as intense exercise. The fact that the patient\u2019s mental status remains intact helps differentiate this condition from central nervous system events. Moreover, the presence of hypokalemia can also predispose to cardiac arrhythmias, which underscores the urgency of identifying the electrolyte abnormality. The initial and most critical diagnostic step is measuring the serum potassium level. Differential diagnoses include thyrotoxic periodic paralysis (which also shows hypokalemia), other electrolyte disturbances, and metabolic myopathies. While tests such as serum calcium, creatine kinase, or thyroid function tests might be useful later, they are not as immediately informative when acute potassium imbalance is suspected. In an acute episode, the first-line treatment involves careful potassium supplementation (oral or intravenous, depending on severity), with continuous cardiac monitoring in severe cases. Preventive strategies include avoiding known triggers. For long-term management, carbonic anhydrase inhibitors like acetazolamide may be used in hereditary forms. In pregnancy or lactation, potassium replacement remains the mainstay, but dosing must be carefully monitored, as maternal and fetal potassium homeostasis is critical. The marked option\u2014serum potassium measurement\u2014is correct. Alternative tests such as serum calcium levels, CK, thyroid function tests, or EMG are either less directly related to the acute presentation or are adjunctive in confirming secondary causes but not as immediately helpful for acute management. \u2022 Intense exercise can precipitate episodes of hypokalemic periodic paralysis in predisposed individuals. \u2022 Normal mental status during weakness points towards an electrolyte disturbance rather than a central nervous disorder. \u2022 Prompt potassium measurement and replacement are crucial to avoid complications like arrhythmias. Recent research emphasizes the importance of early detection of hypokalemia in patients with episodic weakness. Current guidelines stress rapid correction of potassium levels to mitigate risks, and there is a growing use of genetic testing in recurrent cases to determine the specific channelopathy involved.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "35 years old female obese, has delayed muscle relaxation, complaining of tingling in her hands and has slight bradycardia in her VS, what investigation to do?",
    "option_a": "TFT",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical picture of an obese 35\u2010year\u2010old woman with delayed muscle relaxation, tingling in her hands, and slight bradycardia is highly suggestive of hypothyroidism. The delayed relaxation phase of deep tendon reflexes is a classic sign, making thyroid function tests (TFT) the appropriate investigation. In hypothyroidism, reduced thyroid hormone levels lead to a decreased metabolic rate, affecting neuromuscular function. The altered deposition of substances such as glycosaminoglycans in tissues slows muscle contraction and relaxation. Additionally, reduced sympathetic activity contributes to bradycardia. The presence of delayed muscle relaxation corresponds with the classic 'hung-up' reflex seen in hypothyroid patients. Tingling sensations can be related to associated entrapment neuropathies (e.g., carpal tunnel syndrome) frequently seen in hypothyroidism. Bradycardia further supports low thyroid hormone activity. The first-line diagnostic test is a thyroid function test, including TSH and free T4 levels. Differential diagnoses might include isolated neuromuscular or neuropathic conditions; however, the systemic signs point towards an endocrine cause. Management initially involves thyroid hormone replacement with levothyroxine, tailored to the patient\u2019s weight and clinical status. Regular monitoring of TSH and free T4 is needed to adjust dosing. During pregnancy and lactation, levothyroxine is safe and necessary, with increased dosage requirements often observed to maintain euthyroid status and ensure fetal development. Option A (TFT) is correct because it directly evaluates the thyroid hormone levels responsible for the patient\u2019s symptoms. Other investigations would not comprehensively address the systemic manifestations observed. \u2022 Delayed relaxation of deep tendon reflexes is a highly sensitive indicator of hypothyroidism. \u2022 Hypothyroidism frequently presents with nonspecific symptoms such as fatigue and weight gain, along with more specific signs like bradycardia and neuropathic symptoms. \u2022 Early detection through TFT can prevent long-term complications. Recent guidelines advocate for early TFT screening in patients with compatible symptoms. The emphasis on monitoring thyroid hormone levels, particularly in special populations like pregnant and lactating women, has been reinforced by updated endocrine society recommendations.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case of about neurofascin 51 what is the appropriate treatment",
    "option_a": "Rituximab",
    "option_b": "IVIG",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question addresses a neuropathy associated with antibodies against nodal/paranodal proteins, specifically neurofascin. The detection of such antibodies defines a subset of chronic inflammatory demyelinating polyneuropathy (CIDP) that may not respond to standard treatments. Anti-neurofascin antibodies, often of the IgG4 subclass, target cell adhesion molecules critical for proper node of Ranvier structure. This autoimmune attack disrupts nerve conduction by affecting the paranodal architecture, leading to demyelination and conduction block. Patients with neurofascin-associated neuropathies may present with a subacute or chronic progressive course, featuring motor and sensory deficits sometimes accompanied by tremor and ataxia. These patients often show a poor response to IVIG or corticosteroids compared to typical CIDP cases. Diagnosis involves nerve conduction studies and serological testing for specific antibodies (e.g., anti-neurofascin 155). Differential diagnoses include typical CIDP, multifocal motor neuropathy, and other immune-mediated neuropathies. Identification of the antibody profile guides the choice of therapy. For typical CIDP, IVIG, corticosteroids, and plasma exchange are first-line therapies. However, in cases associated with anti-neurofascin antibodies, these patients tend to have a limited response to such treatments. Rituximab, an anti-CD20 monoclonal antibody that decreases B-cell mediated autoimmunity, is considered a superior option. In pregnant or lactating patients, caution with rituximab is recommended due to potential risks to the fetus or neonate, and alternative immunomodulatory strategies should be considered. Option A (Rituximab) is correct as it specifically targets the B-cell driven autoimmune process underlying neurofascin antibody-positive neuropathy. IVIG (option B) is less effective in this subset, and other options either do not address the underlying pathology or are less evidence-based in this context. \u2022 Anti-neurofascin neuropathies represent a distinct immunological subset of CIDP with a poor response to conventional therapies. \u2022 Rituximab has emerged as an effective treatment in these challenging cases. \u2022 Serological testing for nodal/paranodal antibodies should be performed in CIDP cases that are refractory to standard therapy. Recent studies and clinical experiences have increasingly supported the use of rituximab in patients with paranodal antibody-positive CIDP, with several guidelines now recommending its use in refractory cases. Ongoing research continues to refine patient selection and optimize dosing strategies.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "anti MUSK patient who developed hepatotoxicity with azathioprine, what medication to give her?",
    "option_a": "Rituximab",
    "option_b": "Prednisolone",
    "option_c": "Monthly IVIG",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The case involves an anti-MuSK myasthenia gravis patient who has developed hepatotoxicity from azathioprine. This necessitates an alternative immunosuppressive strategy that effectively targets the autoimmune process in MuSK MG. In myasthenia gravis, autoantibodies target proteins at the neuromuscular junction, impairing signal transmission. In anti-MuSK MG, antibodies against muscle-specific kinase disrupt postsynaptic organization. While azathioprine helps reduce antibody production, its adverse effect of hepatotoxicity makes its continued use unsafe in this patient. Anti-MuSK MG often presents with severe bulbar and facial muscle weakness and has a distinct response pattern compared to anti-AChR MG. When adverse effects from medications such as azathioprine occur, choosing an alternative that controls the autoimmune response is crucial. When hepatotoxicity is noted, liver function tests should be monitored and the treatment regimen reassessed. The differential after discontinuing azathioprine includes other immunosuppressants such as mycophenolate mofetil, tacrolimus, or biologics, with specific consideration for the unique challenges of MuSK MG. First-line treatment generally involves acetylcholinesterase inhibitors combined with corticosteroids. For patients who develop adverse effects from conventional steroid\u2010sparing agents like azathioprine, rituximab is indicated\u2014especially in anti-MuSK MG due to its robust efficacy. However, in pregnant or lactating patients, rituximab is generally contraindicated or used with extreme caution because it can cross the placenta; in such cases, alternative agents or dose-adjusted corticosteroid regimes may be considered. Option A (Rituximab) is the correct choice as it targets the B-cell mediated autoimmune process central to anti-MuSK MG and has shown efficacy in patients who are refractory or intolerant to conventional immunosuppressants. Prednisolone (option B) is typically already part of the regimen, and monthly IVIG (option C) is more appropriate for acute exacerbations rather than long-term management. \u2022 Anti-MuSK myasthenia gravis can be more refractory to standard therapy and may benefit from early use of rituximab. \u2022 Azathioprine-induced hepatotoxicity necessitates rapid switching to an alternative immunosuppressant. \u2022 Close monitoring is essential when modifying immunosuppressive regimens in myasthenia gravis. Recent clinical trials and observational studies support the efficacy of rituximab in anti-MuSK MG, with many experts advocating for its early use in patients who do not tolerate conventional therapies. Updated guidelines emphasize individualized treatment planning, especially when managing adverse drug reactions like hepatotoxicity.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "34 year old man had difficulty climbing stairs and had also respiratory difficulties requiring BiPap, what is the most likely cause?",
    "option_a": "Acid maltase deficiency",
    "option_b": "Pyruvate kinase",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a 34\u2010year\u2010old man with proximal muscle weakness (difficulty in climbing stairs) and respiratory insufficiency requiring BiPAP support. These are classic features of Pompe disease\u2014a glycogen storage disorder due to acid maltase (acid alpha-glucosidase) deficiency. Pompe disease results from a deficiency in the lysosomal enzyme acid alpha-glucosidase. The defective enzyme prevents proper glycogen breakdown, leading to its accumulation within lysosomes of muscle cells. In late\u2010onset Pompe disease, the predominant involvement of proximal and respiratory muscles is due to the continuous accumulation of glycogen over time. Recent studies continue to reinforce the role of enzyme deficiency in progressive myopathy and respiratory compromise. Patients typically present with slowly progressive limb\u2010girdle muscle weakness and respiratory difficulties. The involvement of respiratory muscles, notably the diaphragm, explains the need for ventilatory support such as BiPAP. Recognition of these key clinical features is essential for early diagnosis and management. Diagnosis is typically achieved by measuring acid alpha-glucosidase enzyme activity, supported by genetic testing for GAA gene mutations. Differential diagnoses include other causes of limb\u2010girdle or metabolic myopathies (such as muscular dystrophies and inflammatory myopathies), though the combination with respiratory failure is quite characteristic for Pompe disease. Muscle biopsy and serum creatine kinase levels may aid in evaluation. The first-line treatment for Pompe disease is enzyme replacement therapy (ERT) with recombinant alglucosidase alfa, which has been shown to improve survival and slow disease progression. Supportive care, including respiratory support and physical therapy, is vital. In pregnant or lactating patients, ERT has been used after careful risk-benefit assessment due to limited data, and multidisciplinary management is recommended. Option A (Acid maltase deficiency) is correct as it directly refers to Pompe disease. Option B (Pyruvate kinase deficiency) is incorrect since it is associated with hemolytic anemia rather than a myopathy. 1) Late-onset Pompe disease often presents with a combination of proximal muscle weakness and respiratory insufficiency. 2) Enzyme replacement therapy is the cornerstone of management and can improve outcomes if started early. 3) Always consider Pompe disease in adults with unexplained respiratory muscle involvement. Recent guidelines and clinical trials have underscored the benefit of early initiation of ERT to improve respiratory function and overall survival. Ongoing research focuses on optimizing dosing strategies and exploring combination therapies to further slow disease progression.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Anti musk case which is true?",
    "option_a": "Normal thymus pathology",
    "option_b": "Associated with HLA DRB8",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Anti-MuSK myasthenia gravis is a subtype of myasthenia gravis characterized by autoantibodies against muscle-specific kinase (MuSK) rather than the more common acetylcholine receptor antibodies. The typical thymic pathology seen in AChR-positive MG (such as thymic hyperplasia) is generally not observed in the anti-MuSK variant. In anti-MuSK myasthenia gravis, the antibodies disrupt MuSK function, impairing postsynaptic clustering of acetylcholine receptors at the neuromuscular junction. The pathogenesis is distinct from that of classic myasthenia gravis, and as a result, thymic abnormalities like hyperplasia or thymoma are less common, leading to a normal thymic pathology in many patients. Patients with anti-MuSK MG often present with more pronounced bulbar, facial, and respiratory involvement compared to those with AChR-positive MG. The absence of thymic pathology is a key distinguishing feature that guides both diagnosis and management. The diagnosis is confirmed by detecting anti-MuSK antibodies and differentiating from AChR antibody-positive MG. Electrophysiological studies (such as repetitive nerve stimulation and single-fiber EMG) can support the diagnosis. Differential diagnoses include other neuromuscular junction disorders and atypical presentations of MG. Management of anti-MuSK MG typically involves immunosuppressive therapies such as corticosteroids and steroid-sparing agents (e.g., azathioprine, mycophenolate mofetil). Unlike AChR-positive MG, thymectomy is not routinely recommended given the lack of thymic pathology. In pregnant or lactating patients, immunosuppressants must be selected with caution, and a multidisciplinary team approach is essential to balance disease control with fetal safety. Option A (Normal thymus pathology) is correct for anti-MuSK MG. Option B (Associated with HLA DRB8) is not well established in the literature as a defining feature of anti-MuSK MG. 1) Anti-MuSK MG often presents with predominant bulbar and respiratory symptoms. 2) Normal thymic pathology differentiates it from the AChR-positive MG variant. 3) Thymectomy is generally not beneficial in anti-MuSK cases. Recent consensus guidelines and studies from neuromuscular foundations emphasize tailored immunosuppressive treatment for anti-MuSK MG. There is ongoing research into targeted therapies that address the unique pathogenic mechanisms in this MG subtype.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "40 years old man, developed ankle dorsiflexion weakness, sensation over dorsum of the foot was decreased what structure is most likely affected?",
    "option_a": "Lateral portion of sciatic nerve",
    "option_b": "Medial portion of sciatic nerve",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical presentation of a 40-year-old man with ankle dorsiflexion weakness and decreased sensation over the dorsum of the foot is most consistent with a lesion affecting the nerve supply to the muscles responsible for dorsiflexion, which is the common peroneal (fibular) nerve. This nerve arises from the lateral division of the sciatic nerve. The common peroneal nerve, which constitutes the lateral portion of the sciatic nerve, innervates the anterior compartment of the leg, including the dorsiflexors (e.g., tibialis anterior) as well as provides sensory innervation to the dorsum of the foot. An injury or pathology affecting this component leads to foot drop and sensory deficits. Dorsiflexion weakness (foot drop) and impaired sensation over the dorsum of the foot are classic signs of common peroneal nerve involvement. These findings correlate directly with a lesion in the lateral component of the sciatic nerve before its bifurcation. Workup typically includes nerve conduction studies and electromyography (EMG) to localize the lesion. Magnetic resonance imaging (MRI) of the lumbar spine or the knee (depending on the suspected site of injury) can help rule out other causes such as L5 radiculopathy. Differential diagnoses include lumbar radiculopathy, peripheral neuropathy, or compressive mononeuropathy. Initial management includes addressing any reversible causes (e.g., compression or trauma), physical therapy, and use of an ankle-foot orthosis (AFO) to assist with gait. In cases where an underlying compressive lesion is identified, surgical decompression may be indicated. In pregnant patients or those who are lactating, conservative management is preferred, and interventions are tailored to minimize risk while restoring function. Option A (Lateral portion of the sciatic nerve) is correct since it gives rise to the common peroneal nerve, which is responsible for dorsiflexion and sensory supply to the dorsum of the foot. Option B (Medial portion of the sciatic nerve) is incorrect because it forms the tibial nerve, which primarily supplies the posterior compartment and plantar aspects of the foot. 1) Foot drop with sensory loss over the dorsum of the foot is a hallmark of common peroneal nerve involvement. 2) Differentiating between the lateral (fibular) and medial (tibial) divisions of the sciatic nerve is crucial in localizing the lesion. 3) Early EMG and nerve conduction studies can help in the timely diagnosis and management of peripheral nerve injuries. Recent studies advocate for early intervention and accurate localization of nerve lesions using advanced neurophysiological techniques. The role of conservative management with physical therapy and orthotic support is well-established, with surgical options reserved for refractory or compressive lesions.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case of young man, who had myotonia and warm up which improved after exercise his father had the same dx, what is most likely dx?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Thoms",
    "subspecialty": "Neuromuscular",
    "explanation": "The case describes a young man with myotonia and a warm-up phenomenon (improved stiffness with exercise), along with a positive family history (his father had the same diagnosis). This clinical picture is characteristic of myotonia congenita, specifically Thomsen's disease, which is inherited in an autosomal dominant manner. Thomsen's disease is caused by mutations in the CLCN1 gene that encodes the skeletal muscle chloride channel. The defective chloride ion conductance leads to delayed muscle relaxation (myotonia) after contraction. The warm-up phenomenon, in which repeated use of the muscle temporarily alleviates stiffness, is a hallmark distinguishing feature. Patients typically present with muscle stiffness which improves with continued activity. The autosomal dominant inheritance pattern, as evidenced by a similar diagnosis in the father, supports the diagnosis of Thomsen's disease rather than the autosomal recessive Becker's myotonia congenita or other myotonic disorders. Diagnosis is based on clinical history, electromyography (EMG) showing characteristic myotonic discharges, and genetic testing confirming mutations in the CLCN1 gene. Differential diagnoses include myotonic dystrophy (which usually has systemic involvement such as cataracts, cardiac conduction defects, and balding), paramyotonia congenita (worsening with exercise or cold), and hyperkalemic periodic paralysis (characterized by episodic weakness rather than persistent myotonia). Management is largely symptomatic. Mexiletine, a sodium channel blocker, is considered first-line treatment to reduce myotonia. Supportive care with physical therapy is also beneficial. In pregnancy and lactation, the use of mexiletine should be approached cautiously with an evaluation of risks versus benefits as data in these populations are limited; non-pharmacological therapies and close monitoring are advisable. The provided option (Thomsen's disease) is correct. It is distinguished from Becker\u2019s disease by its autosomal dominant inheritance and milder symptoms, from myotonic dystrophy by the absence of multisystem involvement, and from paramyotonia congenita by the typical improvement with exercise (warm-up phenomenon). 1) The warm-up phenomenon is a distinctive clinical sign in myotonia congenita that helps differentiate it from other myotonic disorders. 2) An autosomal dominant inheritance pattern strongly favors the diagnosis of Thomsen's disease over Becker's disease. 3) EMG plays a crucial role in confirming the diagnosis. Recent research continues to explore the efficacy of sodium channel blockers like mexiletine in reducing myotonia. Updated guidelines emphasize individualized management plans and the importance of genetic counseling for affected families.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case of a young female, who developed episodic and recurrent weakness in different site on compression ulnar at elbow, common peroneal at fibular head etc, asking about the cause?",
    "option_a": "PMP22 deletion",
    "option_b": "PMP 22 duplication",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) is a genetic disorder affecting peripheral nerves, characterized by recurrent episodes of focal nerve palsies at common sites of compression (e.g., ulnar nerve at the elbow, peroneal nerve at the fibular head). The condition results from a genetic defect in the peripheral myelin protein PMP22. HNPP is most commonly caused by a deletion of the PMP22 gene, which leads to reduced production of PMP22 protein essential for normal myelin maintenance. The deficient myelin becomes less resilient, making nerves more vulnerable to pressure or minor trauma. This predisposition leads to conduction block and transient focal neuropathies. Clinically, patients present with episodic and recurrent episodes of numbness and weakness, especially following minor compressive forces. The involvement at common entrapment sites is a hallmark of HNPP. Although both genders can be affected, the pattern of transient, focal deficits following minor trauma is typical. Diagnosis is made through a combination of clinical history, nerve conduction studies (which often reveal focal slowing or conduction block at pressure points), and confirmatory genetic testing for PMP22 deletion. Differential diagnoses include compressive mononeuropathies from external injury, diabetic neuropathy, and Charcot-Marie-Tooth disease type 1A (which is due to PMP22 duplication). Management of HNPP is primarily supportive. First-line strategies involve patient education on avoiding prolonged or repeated pressure on vulnerable nerves, ergonomic modifications, and physical therapy to maintain function. There is no specific pharmacologic treatment available. In the context of pregnancy or lactation, management remains conservative because there is no need for teratogenic drugs; instead, focus on lifestyle adjustments and possibly splinting to prevent nerve compression. Option A (PMP22 deletion) is correct because HNPP is directly linked to the deletion of the PMP22 gene. Option B (PMP22 duplication) is incorrect as it is associated with Charcot-Marie-Tooth type 1A, which has a different clinical progression and presentation. 1. Recurrent, painless focal neuropathies at common entrapment sites are characteristic of HNPP. 2. Genetic testing for PMP22 deletion confirms the diagnosis. 3. Prevention of nerve compression through lifestyle modifications is the cornerstone of management. Recent studies support the role of PMP22 deletion in the pathogenesis of HNPP and emphasize the importance of early diagnosis to prevent complications. Current guidelines recommend conservative management with emphasis on patient education and avoidance of triggers, as no disease-modifying therapy is available.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "elderly patient intubated with intact LOC but only able to move his EOM, next step in work up?",
    "option_a": "NCS with RNS",
    "option_b": "EEG",
    "option_c": "MRI Brain",
    "option_d": "urine toxicology",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The described clinical scenario is suggestive of a brainstem pathology, most notably locked-in syndrome, where the patient is conscious but unable to move except through preserved eye movements. This condition occurs due to a focal lesion in the brainstem, typically the ventral pons. Locked-in syndrome usually results from a ventral pontine infarct, often due to basilar artery occlusion. The lesion damages the corticospinal and corticobulbar tracts responsible for voluntary movement while sparing the reticular activating system and vertical eye movement pathways. This explains the preservation of consciousness and extraocular motility despite widespread paralysis. In the presented case, the patient is intubated but shows intact level of consciousness and the ability to move only the extraocular muscles. These findings are highly indicative of locked-in syndrome. The clinical picture contrasts with other neuromuscular or metabolic conditions where either consciousness is altered or additional muscle groups are involved. The next best step is neuroimaging. MRI of the brain, particularly with diffusion-weighted imaging, is essential to detect brainstem (pontine) infarcts. Differential diagnoses include neuromuscular junction disorders (e.g., myasthenia gravis evaluated with NCS/RNS), toxic/metabolic encephalopathy (which may prompt urine toxicology), and seizure disorders (where EEG might be used). However, the preserved consciousness with selective motor deficits primarily points towards a structural lesion in the brainstem. First-line management for a brainstem infarct involves emergent evaluation for reperfusion therapies (e.g., IV thrombolysis or mechanical thrombectomy) if the patient is within the appropriate time window. Supportive care in an intensive care unit with focus on respiratory and nutritional support is vital. For patients in this scenario, multidisciplinary rehabilitation is key. Though the typical locked-in syndrome patient is not pregnant, similar supportive and non-pharmacological measures are applied for pregnant or lactating patients when imaging with MRI is indicated, as modern MRI protocols are safe in these settings. Option A (NCS with RNS) is inappropriate, as it is meant for neuromuscular junction disorders. Option B (EEG) is used for evaluating seizure activity and encephalopathy. Option D (urine toxicology) targets toxic/metabolic causes. Option C (MRI Brain) is correct as it directly visualizes the brainstem lesion responsible for the clinical symptoms. 1. Preservation of consciousness with isolated extraocular movement suggests locked-in syndrome. 2. MRI is the diagnostic modality of choice for brainstem infarcts. 3. Rapid recognition and management are critical in acute stroke syndromes. Contemporary stroke guidelines advocate for rapid neuroimaging to confirm brainstem infarcts. Recent improvements in MRI technology enhance early detection, which is essential for timely reperfusion therapy and improved outcomes, aligning with current best-practice recommendations.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "16 years old patient has difficulty climbing stairs, positive Gower sign, had scaapular wining",
    "option_a": "Calpainopathy",
    "option_b": "Dysferilinopathy",
    "option_c": "Deuchene muscular dystrophy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Calpainopathy refers to Limb-Girdle Muscular Dystrophy type 2A (LGMD2A), a genetic muscle disorder characterized by progressive proximal muscle weakness. Classic clinical manifestations include difficulty climbing stairs and a positive Gower sign, indicative of proximal lower limb weakness, combined with scapular winging. Mutations in the CAPN3 gene result in a deficiency or dysfunction of the calpain-3 protease, which plays a crucial role in muscle repair and maintenance. The resulting impaired proteolysis leads to gradual muscle fiber degeneration, predominantly affecting the pelvic and shoulder girdles. A 16-year-old with difficulty climbing stairs, a positive Gower sign, and scapular winging fits the profile of LGMD2A. While scapular winging is seen in several neuromuscular disorders, in the context of these other findings and the patient\u2019s age, calpainopathy is the most likely diagnosis. It is differentiated from other dystrophies by its pattern of muscle involvement and age of onset. Diagnostic evaluation typically begins with serum creatine kinase (CK) levels, which are usually elevated in muscle dystrophies. Electromyography (EMG) demonstrates a myopathic pattern, and muscle biopsy reveals dystrophic changes. Definitive diagnosis is obtained through genetic testing for CAPN3 mutations. Differential diagnoses include Duchenne Muscular Dystrophy (typically presenting earlier with X-linked inheritance) and Dysferlinopathy (LGMD2B), which tends to have slightly different clinical and morphological features. Management is largely supportive, focusing on physical therapy to preserve mobility, strength, and joint range, and on orthopedic interventions to manage contractures. No curative treatment exists at present, although gene therapy and other experimental strategies are under investigation. In pregnant or lactating patients, management remains supportive with careful monitoring and appropriate rehabilitation strategies, as no specific medications that would compromise fetal safety are used. Option A (Calpainopathy) correctly identifies LGMD2A. Option B (Dysferlinopathy) refers to LGMD2B, which, while similar, shows different clinical features and is less associated with scapular winging. Option C (Deuchene muscular dystrophy), likely intended to denote Duchenne Muscular Dystrophy, typically presents in early childhood and follows a more severe course. Thus, option A is the most appropriate answer. 1. A positive Gower sign is a classic sign of proximal muscle weakness. 2. LGMD2A (calpainopathy) typically presents in adolescence with both pelvic and shoulder girdle involvement. 3. Scapular winging in the setting of proximal weakness favors an LGMD over other muscular dystrophies. Recent studies are focused on better characterizing the genetic mutations involved in LGMD2A and exploring potential gene therapy options. Current guidelines stress the importance of early genetic and laboratory investigations to establish a definitive diagnosis and guide supportive management.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case of hirayama disase (came twice), weakness in distal hand and forearm muscles which progressed over 18 months then become static, asking about what is the Dx?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Hiray",
    "subspecialty": "Neuromuscular",
    "explanation": "Hirayama disease, also known as monomelic amyotrophy, is a benign, self-limiting focal motor neuron disease that primarily affects young males. It is characterized by insidious onset of asymmetrical weakness and atrophy in the distal muscles of the upper limb, most notably in the hand and forearm. The underlying mechanism involves a dynamic compression of the lower cervical spinal cord during neck flexion. This is thought to be due to an imbalance in growth between the vertebral column and its dural sac, leading to anterior displacement of the posterior dura. The resultant chronic microcirculatory disturbances and ischemia of the anterior horn cells lead to motor neuron loss. Patients typically present with gradually progressive weakness and atrophy of the distal upper limb muscles that usually progress over 1-2 years before reaching a plateau. Sensory functions are characteristically spared. These features help distinguish Hirayama disease from other motor neuron disorders that have both upper and lower motor neuron involvement. Diagnosis relies on a combination of clinical findings and imaging studies. A key diagnostic tool is a flexion MRI of the cervical spine, which demonstrates forward displacement of the posterior dural sac and consequent flattening of the spinal cord. Differential diagnoses include amyotrophic lateral sclerosis (ALS), which shows a relentlessly progressive course with mixed upper and lower motor neuron signs, multifocal motor neuropathy (MMN) with conduction block on neurophysiology, cervical spondylotic myelopathy typically seen in older adults, and spinal muscular atrophy (SMA), which has an earlier onset and symmetric involvement. The mainstay of management for Hirayama disease is conservative. The first-line treatment involves the use of a cervical collar to prevent neck flexion and further cord compression. Physical therapy is employed to maintain strength and function. In rare cases of progressive disease beyond the typical plateau, surgical options such as cervical laminoplasty may be considered. Although Hirayama disease predominantly affects young males, in any patient (including pregnant or lactating individuals) who might rarely present with similar findings, conservative management remains the first-line approach due to its favorable safety profile. The marked answer indicating Hirayama disease is correct. Alternative conditions such as ALS, MMN, cervical spondylotic myelopathy, and SMA were considered; however, each presents with either continuous progression with both upper and lower motor neuron signs (ALS), neurophysiologic evidence of conduction block (MMN), older age and mixed findings (cervical spondylotic myelopathy), or earlier and symmetric onset (SMA). The clinical presentation described fits Hirayama disease perfectly. 1. Hirayama disease typically presents in young males with asymmetric distal upper limb weakness that plateaus after a progressive phase. 2. Flexion MRI of the cervical spine is instrumental in confirming the diagnosis. 3. Conservative management with a cervical collar is the first-line treatment. Recent advances in imaging have sharpened the diagnostic approach for Hirayama disease, emphasizing flexion MRI to capture dynamic changes in the cervical spine. Current guidelines advocate conservative management as the initial treatment modality, with surgery reserved for select cases demonstrating continued progression.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young adult has progressive bilateral painless decrease in visual acuity over 2-3 years, his brother has similar symptoms few years ago, what should be testing in this patient? (Case of Leber\u2019s disease)",
    "option_a": "ECG",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Leber\u2019s hereditary optic neuropathy (LHON) is a mitochondrial disorder that primarily affects young adults, leading to a bilateral, painless, and progressive loss of central vision. Its maternal inheritance pattern is a hallmark, and a positive family history (as seen with the affected brother) is common. LHON is caused by point mutations in mitochondrial DNA (most notably G11778A, T14484C, and G3460A) that impair the mitochondrial respiratory chain. This leads to underproduction of ATP and increased production of reactive oxygen species, resulting in the selective degeneration of retinal ganglion cells and optic nerve fibers. Patients typically experience a subacute, bilateral loss of visual acuity without pain. The disease can initially affect one eye followed by the other; however, variability exists. The family history further supports its genetic and mitochondrial basis. The work\u2010up for suspected LHON includes a detailed ophthalmologic evaluation with optical coherence tomography and visual evoked potentials along with confirmatory genetic testing to identify the mitochondrial DNA mutations. Differential diagnoses include toxic, nutritional, or ischemic optic neuropathies which may be differentiated based on history, exam, and ancillary testing. There is no curative treatment for LHON. Management focuses on lifestyle modifications (avoiding tobacco and excessive alcohol) and the use of idebenone, a short-chain benzoquinone, which has shown some benefit when initiated early. Genetic counseling is advised. In pregnancy and lactation, treatment decisions must be cautious; idebenone is generally used under close supervision, and supportive measures are emphasized. Option A (ECG) may be performed in some patients due to reports of cardiac conduction defects in mitochondrial diseases; however, the main diagnostic test for LHON is mitochondrial DNA analysis (presumably Option B). Thus, Option B is the correct answer as it directly addresses the confirmation of the mitochondrial mutation responsible for the condition. \u2022 LHON typically presents with painless, bilateral visual loss in a young patient with a family history.  \u2022 Mitochondrial DNA testing is essential for diagnosis.  \u2022 The disorder is maternally inherited, so male-to-male transmission does not occur. Recent studies continue to evaluate and refine the role of idebenone and other agents in LHON, while genetic testing techniques have become more sensitive. Research into gene therapy is ongoing, and current guidelines support a multidisciplinary approach including genetic counseling and lifestyle modifications.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case of refsums disease, patient had trouble vision during night and has polyneuroapthy , what is the diagnosis?",
    "option_a": "refsums",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Refsum disease is a peroxisomal disorder characterized by the accumulation of phytanic acid due to a defect in its alpha\u2010oxidation. It classically presents with retinitis pigmentosa (leading to difficulty with night vision), peripheral neuropathy, cerebellar ataxia, and sometimes skin changes (ichthyosis). A deficiency of the enzyme phytanoyl-CoA hydroxylase results in impaired oxidation of phytanic acid, a branched-chain fatty acid. The accumulation of phytanic acid in tissues, particularly in the retina and peripheral nerves, produces toxic effects that lead to the clinical manifestations of the disorder. Patients commonly develop night blindness due to retinal degeneration (similar in appearance to retinitis pigmentosa) along with polyneuropathy, which results in symptoms such as numbness, tingling, or weakness. The diagnosis is confirmed by measuring elevated plasma levels of phytanic acid. Differential diagnoses include other causes of retinitis pigmentosa and peripheral neuropathies such as vitamin A deficiency or other metabolic disorders, but the combination of features along with an abnormal plasma phytanic acid level is diagnostic of Refsum disease. The cornerstone of management is the reduction of phytanic acid levels through strict dietary restrictions (avoiding foods high in phytanic acid such as dairy products, ruminant fats, and certain fish). Physical therapy may help with neuropathic symptoms, and regular ophthalmologic follow-up is important. During pregnancy and lactation, dietary modifications should be carefully managed in consultation with a metabolic specialist to ensure adequate nutrition while lowering phytanic acid intake. Option A, which identifies the diagnosis as Refsum disease, is correct because the patient\u2019s presentation of night vision difficulties combined with polyneuropathy strongly suggests the accumulation of phytanic acid associated with this condition. \u2022 Refsum disease should be suspected when a patient presents with night blindness and peripheral neuropathy.  \u2022 Measuring plasma phytanic acid levels is key for diagnosis.  \u2022 Dietary modification is the mainstay of therapy. Recent guidelines emphasize early dietary intervention to reduce phytanic acid levels and prevent progression of neurological and ocular manifestations. Studies are currently exploring additional therapies to manage and ameliorate the long\u2010term complications.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "16 years old patient has difficulty climbing stairs, positive Gower sign, on exam has bilateral scapular winging. His parents are first degree cousins, and his sister is affected as well, what is the most likely diagnosis?",
    "option_a": "Calpainopathy",
    "option_b": "Dysferlinopathy",
    "option_c": "Duchenne muscular dystrophy",
    "option_d": "Facioscapulohumeral muscular dystrophy",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Calpainopathy, commonly categorized as limb\u2010girdle muscular dystrophy type 2A (LGMD2A), is an autosomal recessive disorder due to mutations in the CAPN3 gene. It affects both sexes and typically presents in adolescence with proximal muscle weakness. Mutations in the CAPN3 gene result in a deficiency of calpain-3, a muscle-specific protease involved in sarcomere remodeling. This leads to progressive muscle fiber damage and replacement by fibrous tissue, manifesting clinically as muscle weakness and atrophy. The patient\u2019s difficulty with climbing stairs and a positive Gower sign are indicative of proximal muscle weakness. Bilateral scapular winging further supports involvement of the shoulder girdle. The history of consanguinity and an affected sister points toward an autosomal recessive pattern, making calpainopathy (LGMD2A) the most likely diagnosis. Evaluation includes measurement of serum creatine kinase levels, electromyography, and ultimately genetic testing to confirm mutations in the CAPN3 gene. Differential diagnoses include other forms of limb-girdle muscular dystrophy (such as dysferlinopathy), Duchenne muscular dystrophy (which is X-linked and usually does not affect females), and facioscapulohumeral muscular dystrophy (which has a different pattern of muscle involvement). Management is largely supportive and includes physical therapy, occupational therapy, and the use of assistive devices. Regular cardiac and respiratory evaluation is recommended, although cardiac involvement is less common in LGMD2A compared to other muscular dystrophies. Genetic counseling is an integral part of care. In pregnancy and lactation, a multidisciplinary approach is essential, with physiotherapy and close monitoring to manage symptoms and maintain function. \u2022 Option A (Calpainopathy): Correct \u2013 It fits the clinical presentation, inheritance pattern, and physical examination findings.  \u2022 Option B (Dysferlinopathy): Typically presents with later onset and often with a different pattern of muscle involvement.  \u2022 Option C (Duchenne muscular dystrophy): X-linked and primarily affects boys, making it unlikely when a sister is also affected.  \u2022 Option D (Facioscapulohumeral muscular dystrophy): Typically presents with facial weakness and asymmetric scapular involvement, which is not described here. \u2022 A positive Gower sign is a classic indicator of proximal muscle weakness.  \u2022 Consanguinity and multiple affected siblings point towards an autosomal recessive disorder.  \u2022 LGMD2A frequently manifests during adolescence. Current research in LGMD focuses on genetic therapies and improved supportive care measures. Although there is no curative treatment yet, early diagnosis and intervention can improve quality of life and functional outcomes.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A Young healthy man with sudden foot drop and attached nerve conduction table (showing normal sensory and motor, except for drop in amplitude across the fibular head from 5 to 1.9 with reduced velocity in motor peroneal), asking what is the pathology and prognosis?",
    "option_a": "Demyelination with rapid recovery",
    "option_b": "Demyelination with poor recovery",
    "option_c": "Axonal with rapid recovery",
    "option_d": "Axonal with partial recovery",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The common peroneal (fibular) nerve, particularly at the level of the fibular head, is vulnerable to compressive neuropathy, which is a prevalent cause of sudden foot drop in otherwise healthy individuals. The pathology in such cases is often demyelination secondary to compression. In compressive neuropathies, mechanical pressure on the nerve leads to segmental demyelination. This results in conduction block or slowing across the affected segment, which is evident on nerve conduction studies. Importantly, if the axons remain intact, demyelination is recoverable with remyelination and relief of the compressive force. The patient\u2019s presentation of sudden foot drop aligns with common peroneal nerve entrapment. The nerve conduction study findings, with a significant drop in amplitude (from 5 to 1.9) and reduced conduction velocity across the fibular head, are characteristic of a demyelinating process rather than an axonal injury. The differential diagnosis in sudden foot drop includes lumbar radiculopathy, other peripheral neuropathies, and central causes such as stroke. However, focal deficits localized to the distribution of the peroneal nerve along with localized nerve conduction abnormalities support the diagnosis of a compressive neuropathy. High-resolution imaging (ultrasound or MRI) may be used to evaluate for structural causes if clinically indicated. The first-line management of peroneal nerve entrapment includes conservative measures such as physical therapy, avoidance of prolonged leg crossing, and the use of orthotic devices if necessary. If symptoms persist, more invasive approaches such as nerve decompression surgery may be considered. In pregnancy and lactation, conservative treatment is preferred to avoid surgical risks and medication exposure; physical therapy and careful positional adjustments are safe and effective. \u2022 Option A (Demyelination with rapid recovery): This is correct because the conduction study findings are most consistent with a demyelinating lesion due to compression, which typically recovers rapidly once the compressive factor is resolved.  \u2022 Option B (Demyelination with poor recovery): Incorrect, as demyelinating lesions generally have a good prognosis if treated early.  \u2022 Option C (Axonal with rapid recovery): Axonal injuries usually result in a reduced amplitude without significant slowing of conduction velocity and have a slower recovery due to the need for axonal regeneration.  \u2022 Option D (Axonal with partial recovery): Incorrect for similar reasons; axonal damage does not typically present with rapid recovery. \u2022 The common peroneal nerve is highly susceptible to compression around the fibular head.  \u2022 Demyelinating lesions, unlike axonal injuries, often recover rapidly once the compressive insult is removed.  \u2022 Nerve conduction studies are crucial in differentiating between demyelinating and axonal pathologies. Recent studies emphasize the importance of early intervention in compressive neuropathies to prevent permanent damage. Current guidelines advocate for conservative management initially, with a strong role for physiotherapy and lifestyle modifications prior to considering surgical intervention.",
    "exam_year": "2024",
    "exam_type": "Part II"
  }
]